The ClinicianThe ClinicianКлиницист1818-83382412-8775Publishing House ABV Press3210.17650/1818-8338-2013-2-73-80PHARMACOTHERAPYФАРМАКОТЕРАПИЯTHE EFFICIENCY AND SAFETY OF SECONDARY PREVENTION OF ISCHEMIC STROKEПроблемы эффективности и безопасности вторичной профилактики ишемического инсультаKamchatnovP. R.КамчатновП. Р.
Russian Federation
pavkam7@gmail.comKabanovA. A.КабановА. А.
Russian Federation
N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава России150420137273801407201414072014Copyright ©; 2013, Kamchatnov P.R., Kabanov A.A.Copyright ©; 2013, Камчатнов П.Р., Кабанов А.А.2013Kamchatnov P.R., Kabanov A.A.Камчатнов П.Р., Кабанов А.А.https://creativecommons.org/licenses/by/4.0https://klinitsist.abvpress.ru/Klin/article/view/32

Ischemic stroke (IS) is a severe disease associated with high mortality and persistent disability. Prior IS is related to the drastically increased risk of repeat IS. Antiplatelet therapy is an efficient way to prevent repeat IS. Acetylsalicylic acid, the administration of its enteric-coated formulationcan reduce the risk of gastric mucosal lesion, has a special efficacy. The possibilities of using other antiaggregants and indirect anticoagulantsare considered.

Ишемический инсульт (ИИ) – тяжелое заболевание, ассоциированное с высокой летальностью и стойкой инвалидизацией.Перенесенный ИИ связан с резким повышением риска повторного ИИ. Эффективным направлением предупреждения повторного ИИ является антитромбоцитарная терапия. Особой эффективностью обладает ацетилсалициловая кислота, применение которой в виде кишечнорастворимой лекарственной формы позволяет снизить риск развития поражения слизистой желудка. Рассматриваются возможности применения других антиагрегантов и непрямых антикоагулянтов.

ischemic strokesecondary preventionacetylsalicylic acidcardiomagnilwarfarinишемический инсультвторичная профилактикаацетилсалициловая кислотакардиомагнилварфарин1. Гусев Е.И., Скворцова В.И., Стаховская Л.В. Эпидемиология инсульта в России. Журн неврол и психиатр 2003;(прил 8):4–9.Гусев Е.И., Скворцова В.И., Стаховская Л.В. Эпидемиология инсульта в России. Журн неврол и психиатр 2003;(прил 8):4–9.2. Sacco R.L., Adams R., Albers G. et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37(2):577–617.Sacco R.L., Adams R., Albers G. et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37(2):577–617.3. Coull A.J., Lovett J.K., Rothwell P.M.; Oxford Vascular Study. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 2004;328(7435):326.Coull A.J., Lovett J.K., Rothwell P.M.; Oxford Vascular Study. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 2004;328(7435):326.4. Lovett J.K., Coull A.J., Rothwell P.M. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004;62(4):569–73.Lovett J.K., Coull A.J., Rothwell P.M. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004;62(4):569–73.5. Жетишев Р.Р., Камчатнов П.Р., Михайлова Н.А., Иващенко А.Р. Асимптомный инсульт. Журн невролЖетишев Р.Р., Камчатнов П.Р., Михайлова Н.А., Иващенко А.Р. Асимптомный инсульт. Журн невроли психиатр 2013;113(3 прил 2);53–7.6. Vermeer S.E., Hollander M., van Dijk E.J. et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003;34(5):1126–9.Vermeer S.E., Hollander M., van Dijk E.J. et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003;34(5):1126–9.7. Фрис Я.Е., Камчатнов П.Р., Шелякина Л.А. Информированность населения о факторах риска сосудистых заболеваний головного мозга и клинических проявлений инсульта. Журн неврол и психиатр 2010;9(2):3–12.Фрис Я.Е., Камчатнов П.Р., Шелякина Л.А. Информированность населения о факторах риска сосудистых заболеваний головного мозга и клинических проявлений инсульта. Журн неврол и психиатр 2010;9(2):3–12.8. Brott T.G., Halperin J.L., Abbara S. et al. ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. J Am Coll Cardiol 2011;57(8):1002–44.Brott T.G., Halperin J.L., Abbara S. et al. ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. J Am Coll Cardiol 2011;57(8):1002–44.9. Lip G.Y., Kamath S., Hart R.G. ABC of antithrombotic therapy: Antithrombotic therapy for cerebrovascular disorders. BMJ 2002;325(7373):1161–3.Lip G.Y., Kamath S., Hart R.G. ABC of antithrombotic therapy: Antithrombotic therapy for cerebrovascular disorders. BMJ 2002;325(7373):1161–3.10. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trialsAntithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trialsof antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71–86.11. Antithrombotic Trialists' (ATT) Collaboration, Baigent C., Blackwell L., Collins R. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678):1849–60.Antithrombotic Trialists' (ATT) Collaboration, Baigent C., Blackwell L., Collins R. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678):1849–60.12. Wang Y., Wang Y., Zhao X. et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369(1):11–9.Wang Y., Wang Y., Zhao X. et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369(1):11–9.13. Chen Z.M.,Sandercock P., Pan H.C. et al. Indications for early aspirin use in acute ischemic stroke : A combined analysis of40 000 randomized patients from the chinese acute stroke trial and the international stroke trial.On behalf of the CASTand IST collaborative groups. Stroke2000;31(6):1240–9.Chen Z.M.,Sandercock P., Pan H.C. et al. Indications for early aspirin use in acute ischemic stroke : A combined analysis of40 000 randomized patients from the chinese acute stroke trial and the international stroke trial.On behalf of the CASTand IST collaborative groups. Stroke2000;31(6):1240–9.14. Rodríguez L.A., Cea-Soriano L., Martín-Merino E., Johansson S. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ 2011;343:d4094.Rodríguez L.A., Cea-Soriano L., Martín-Merino E., Johansson S. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ 2011;343:d4094.15. Wolff T., Miller T., Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009;150(6):405–10.Wolff T., Miller T., Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009;150(6):405–10.16. Профилактика сердечно-сосудистых заболеваний в клинической практике. Рекомендации Европейского общества кардиологов (пересмотр 2012 г.). Рос кардиол журн 2012;4(96 прил 2):1–84.Профилактика сердечно-сосудистых заболеваний в клинической практике. Рекомендации Европейского общества кардиологов (пересмотр 2012 г.). Рос кардиол журн 2012;4(96 прил 2):1–84.17. Charlot M., Grove E.L., Hansen P.R. et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011;342:d2690.Charlot M., Grove E.L., Hansen P.R. et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011;342:d2690.18. Miner P.B.Jr., Fort J.G., Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (entericcoated aspirin 325 mg + immediaterelease omeprazole 40 mg) or entericcoated aspirin 325 mg + enteric-coated omeprazole 40 mg – a randomised, phase 1, crossover study. Aliment Pharmacol Ther 2013;38(1):62–71.Miner P.B.Jr., Fort J.G., Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (entericcoated aspirin 325 mg + immediaterelease omeprazole 40 mg) or entericcoated aspirin 325 mg + enteric-coated omeprazole 40 mg – a randomised, phase 1, crossover study. Aliment Pharmacol Ther 2013;38(1):62–71.19. Williams B., Poulter N.R., Brown M.J. et al.; BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328(7440):634–40.Williams B., Poulter N.R., Brown M.J. et al.; BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328(7440):634–40.20. Felmeden D.C., Lip G.Y. Antithrombotic therapy in hypertension: a Cochrane Systematic review. J Hum Hypertens 2005;19(3):185–96.Felmeden D.C., Lip G.Y. Antithrombotic therapy in hypertension: a Cochrane Systematic review. J Hum Hypertens 2005;19(3):185–96.21. Berrouschot J., Schwetlick B., von Twickel G. et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006;113(1):31–5.Berrouschot J., Schwetlick B., von Twickel G. et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006;113(1):31–5.22. Michelson A.D., Cattaneo M., Eikelboom J.W. et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005;3(6):1309–11.Michelson A.D., Cattaneo M., Eikelboom J.W. et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005;3(6):1309–11.23. Sacco R.L., Adams R., Albers G. et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006;113(10);e409–49.Sacco R.L., Adams R., Albers G. et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 2006;113(10);e409–49.24. Gage B.F., Waterman A.D., Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285(22):2864–70.Gage B.F., Waterman A.D., Shannon W. et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285(22):2864–70.25. Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010;137(2):263–72.Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010;137(2):263–72.26. Hippisley-Cox J., Coupland C., Brindle P. Derivation and validation of QStroke score for predicting risk of ischemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ 2013;346:f2573.Hippisley-Cox J., Coupland C., Brindle P. Derivation and validation of QStroke score for predicting risk of ischemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ 2013;346:f2573.27. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation:analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154(13):1449–57.Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation:analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154(13):1449–57.28. Lane D.A., Lip G.Y. Use of the CHA(2) DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation 2012;126(7):860–5.Lane D.A., Lip G.Y. Use of the CHA(2) DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation 2012;126(7):860–5.29. Chimowitz M.I., Lynn M.J., Howlett-Smith H. et al.; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352(13):1305–16.Chimowitz M.I., Lynn M.J., Howlett-Smith H. et al.; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352(13):1305–16.30. Donzé J., Clair C., Hug B. et al. Risk of falls and major bleeds in patients on oral anticoagulationDonzé J., Clair C., Hug B. et al. Risk of falls and major bleeds in patients on oral anticoagulationtherapy. Am J Med 2012;125(8):773–8.31. De Schryver E.L., van Gijn J., Kappelle L.J. et al. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischemic stroke. J Neurol 2005;252(11):1316–21.De Schryver E.L., van Gijn J., Kappelle L.J. et al. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischemic stroke. J Neurol 2005;252(11):1316–21.32. De Schryver E.L., Algra A., van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 2006;(2):CD001820.De Schryver E.L., Algra A., van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 2006;(2):CD001820.33. Sacco R.L., Diener H.C., Yusuf S. et al. Aspirin and extended-release dipyridamol versus clopidogrel for recurrent stroke. N Eng J Med 2008;359(12):1238–51.Sacco R.L., Diener H.C., Yusuf S. et al. Aspirin and extended-release dipyridamol versus clopidogrel for recurrent stroke. N Eng J Med 2008;359(12):1238–51.34. Offman E., Schobelock M.J., Brickl R. et al. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole. Am J CardiovascOffman E., Schobelock M.J., Brickl R. et al. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole. Am J CardiovascDrugs 2013;13(2):113–20.35. Diener H.C., Bogousslavsky J., Brass L.M. et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364(9431):331–7.Diener H.C., Bogousslavsky J., Brass L.M. et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364(9431):331–7.36. Wang T.H., Bhatt D.L., Fox K.A. et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J 2007;28(18):2200–7.Wang T.H., Bhatt D.L., Fox K.A. et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J 2007;28(18):2200–7.37. Keller T.T., Squizzato A., Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev 2007;(3):CD005158.Keller T.T., Squizzato A., Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev 2007;(3):CD005158.38. Willmot M., Zhao L., Heptinstall S., Bath P. Triple antiplatelet therapy for secondary prevention of recurrent ischemic stroke. J Stroke Cerebrovasc Dis 2004;13(3):138–40.Willmot M., Zhao L., Heptinstall S., Bath P. Triple antiplatelet therapy for secondary prevention of recurrent ischemic stroke. J Stroke Cerebrovasc Dis 2004;13(3):138–40.39. Niinuma Y., Saito T., Takahashi M. et al. Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J 2013;doi:10.1038/tpj.2013.22. [Epub ahead of print].Niinuma Y., Saito T., Takahashi M. et al. Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J 2013;doi:10.1038/tpj.2013.22. [Epub ahead of print].40. Kim Y.B., Ko M.J., Lee D.G. et al. CYP2C9 mutation affecting the individual variability of warfarin dose requirement. Ann Rehabil Med 2012;36(6):857–60.Kim Y.B., Ko M.J., Lee D.G. et al. CYP2C9 mutation affecting the individual variability of warfarin dose requirement. Ann Rehabil Med 2012;36(6):857–60.41. Castro T.A., Heineck I. Interventions to improve anticoagulation with warfarin. Ther Drug Monit 2012;34(2):209–16.Castro T.A., Heineck I. Interventions to improve anticoagulation with warfarin. Ther Drug Monit 2012;34(2):209–16.42. Uno T., Sugimoto K., Sugawara K., Tateishi T. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther Drug Monit 2008;30(3):276–81.Uno T., Sugimoto K., Sugawara K., Tateishi T. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther Drug Monit 2008;30(3):276–81.43. Holbrook A.M., Pereira J.A., Labiris R. et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165(10):1095–106.Holbrook A.M., Pereira J.A., Labiris R. et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165(10):1095–106.44. Armstrong M.J., Gronseth G., Anderson D.C. et al. Summary of evidencebased guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013;80(22):2065–9.Armstrong M.J., Gronseth G., Anderson D.C. et al. Summary of evidencebased guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013;80(22):2065–9.